AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17234902 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil counts
Number of subjects: 269
Study 17234902 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-8
Number of subjects: 269
Study 17234902 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial densities
Number of subjects: 269
Study 15480278 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate-mifepristone (600 mg given orally)
Number of subjects: 212
Study 15480278 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate-placebo
Number of subjects: 212
Study 15480278 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate-mifepristone (600 mg given orally) with progesterone level 10 ng/l
Number of subjects: 212
Study 15480278 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate-placebo with progesterone level 10 ng/l
Number of subjects: 212
Study 11566521 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 0.1% eyedrops for 2 months after surgery
Number of subjects: 24
Study 11566521 — intervention group
Group type: COMPARATOR
Intervention: Flurbiprofen 0.03% eyedrops for 2 months after surgery
Number of subjects: 24
Study 9636863 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with fluconazole (200 mg once a day for 2 months) and flucytosine (150 mg/(kg.d) for the first 2 weeks)
Number of subjects: 58
Study 9636863 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with fluconazole and flucytosine
Number of subjects: 58
Study 9636863 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole monotherapy (200 mg once a day for 2 months)
Number of subjects: 58
Study 7920128 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum cholesterol concentration
Number of subjects: 22432
Study 7920128 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 22432
Study 7920128 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent use of alcohol
Number of subjects: 22432
Study 3363288 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intraduodenal dose of camostate
Number of subjects: 8
Study 3363288 — intervention group
Group type: COMPARATOR
Intervention: Daily ingestion of camostate for 5 days
Number of subjects: 8
Study 435882 — intervention group
Group type: EXPERIMENTAL
Intervention: Chenic acid (14‐16 mg/kg/day) administered at bedtime
Number of subjects: 16
Study 435882 — intervention group
Group type: COMPARATOR
Intervention: Chenic acid (14‐16 mg/kg/day) administered in the morning
Number of subjects: 16
Study 435882 — intervention group
Group type: COMPARATOR
Intervention: Chenic acid (14‐16 mg/kg/day) administered at mealtimes
Number of subjects: 16
Study 30351172 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation Meditation Tape (RM)
Number of subjects: 20
Study 30351172 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined RM + Relaxation Lighting (RM+L)
Number of subjects: 20
Study 30351172 — intervention group
Group type: EXPERIMENTAL
Intervention: Music Tape (M)
Number of subjects: 20
Study 30351172 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Music + Relaxation Lighting (M+L)
Number of subjects: 20
Study 30351172 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 20
Study 28291511 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal bupivacaine (2 mg/mL)
Number of subjects: 23
Study 28291511 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal bupivacaine (2 mg/mL) with morphine (1 mg/mL)
Number of subjects: 23
Study 26640405 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine
Number of subjects: 45
Study 26640405 — intervention group
Group type: COMPARATOR
Intervention: 3% mepivacaine
Number of subjects: 45
Study 23603619 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume strength training (1 set, twice weekly for 13 weeks)
Number of subjects: 20
Study 23603619 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume strength training (3 sets, twice weekly for 13 weeks)
Number of subjects: 20
Study 21322768 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented milk containing Lactobacillus casei strain Shirota (LcS) for 3 weeks
Number of subjects: 39
Study 21322768 — intervention group
Group type: COMPARATOR
Intervention: Non‐intervention control
Number of subjects: 39
Study 19958108 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine 10% and tropicamide 1% (group 0: type 2 diabetic patients)
Number of subjects: 50
Study 19958108 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine 10% and tropicamide 1% (group 1: non-diabetic patients)
Number of subjects: 50
Study 17540020 — intervention group
Group type: EXPERIMENTAL
Intervention: Perturbation-based training program
Number of subjects: 30
Study 17540020 — intervention group
Group type: COMPARATOR
Intervention: Control group (flexibility/relaxation training)
Number of subjects: 30
Study 15044749 — intervention group
Group type: EXPERIMENTAL
Intervention: SH U 555 C (40 micromol Fe/kg)
Number of subjects: 16
Study 15044749 — intervention group
Group type: EXPERIMENTAL
Intervention: SH U 555 C (5 micromol Fe/kg)
Number of subjects: 16
Study 15044749 — intervention group
Group type: EXPERIMENTAL
Intervention: SH U 555 C
Number of subjects: 16
Study 15044749 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 16
Study 11500288 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration of open-ended test questions by computer
Number of subjects: 1194
Study 11500288 — intervention group
Group type: COMPARATOR
Intervention: Administration of open-ended test questions by paper-and-pencil
Number of subjects: 1194
Study 9929147 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy with external dose > 60 Gy
Number of subjects: 252
Study 9929147 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy
Number of subjects: 252
Study 7917735 — intervention group
Group type: COMPARATOR
Intervention: suxamethonium 0.5 mg kg‐1
Number of subjects: 30
Study 7917735 — intervention group
Group type: EXPERIMENTAL
Intervention: suxamethonium 1.5 mg kg‐1
Number of subjects: 30
Study 7917735 — intervention group
Group type: EXPERIMENTAL
Intervention: suxamethonium 3.0 mg kg‐1
Number of subjects: 30
Study 3045113 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (100 mg)
Number of subjects: 12
Study 3045113 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (50 mg)
Number of subjects: 12
Study 3045113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30649970 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment and Biobehavioral Catch‐up (ABC)
Number of subjects: 120
Study 30649970 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 120
Study 31023863 — intervention group
Group type: COMPARATOR
Intervention: 80 mg/m2 solvent-based paclitaxel (PACL80/w)
Number of subjects: 0
Study 31023863 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/m2 nab-paclitaxel (NAB100/w)
Number of subjects: 0
Study 31023863 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg/m2 nab-paclitaxel (NAB150/w)
Number of subjects: 0
Study 31023863 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg/m2 nab-paclitaxel (NAB150/2w)
Number of subjects: 0
Study 28340118 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Music Therapy (GMT)
Number of subjects: 100
Study 28340118 — intervention group
Group type: COMPARATOR
Intervention: Self-Directed Music Listening (SDML)
Number of subjects: 100
Study 26099758 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraclavicular blockade
Number of subjects: 60
Study 26099758 — intervention group
Group type: EXPERIMENTAL
Intervention: Infraclavicular blockade
Number of subjects: 60
Study 26099758 — intervention group
Group type: EXPERIMENTAL
Intervention: Interscalene blockade
Number of subjects: 60
Study 24303975 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine (5 mg twice a day)
Number of subjects: 12
Study 24303975 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine (5 mg once daily)
Number of subjects: 12
Study 24303975 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 21142269 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 12
Study 21142269 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of paroxetine and itraconazole
Number of subjects: 12
Study 21142269 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 18055020 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects reporting dimness (at least some of the time)
Number of subjects: 213
Study 18055020 — intervention group
Group type: COMPARATOR
Intervention: Subjects never noting dimness
Number of subjects: 213
Study 18055020 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed individuals (CES-D > or = 16)
Number of subjects: 213
Study 18055020 — intervention group
Group type: EXPERIMENTAL
Intervention: Total CES-D score and degree of reported dimness (0-3)
Number of subjects: 213
Study 17925516 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (up to 300 mg/d)
Number of subjects: 371
Study 17925516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 371
Study 15474136 — intervention group
Group type: EXPERIMENTAL
Intervention: Information leaflet plus an appointment with an alcohol health worker
Number of subjects: 599
Study 15474136 — intervention group
Group type: COMPARATOR
Intervention: Information leaflet (control group)
Number of subjects: 599
Study 11114448 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-axis graph representation of joint rotations
Number of subjects: 15
Study 9022117 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.08%
Number of subjects: 194
Study 9022117 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2%
Number of subjects: 194
Study 9022117 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.5%
Number of subjects: 194
Study 9022117 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194
Study 7910235 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased pressure on tissue due to inappropriate sensor fixation (50 mm Hg)
Number of subjects: 20
Study 7910235 — intervention group
Group type: EXPERIMENTAL
Intervention: Venous congestion at 30 mm Hg
Number of subjects: 20
Study 7910235 — intervention group
Group type: EXPERIMENTAL
Intervention: Venous congestion at 40 mm Hg
Number of subjects: 20
Study 3598226 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant leukocyte A interferon (IFN; 9 X 10(6) U per day)
Number of subjects: 100
Study 3598226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 29623574 — intervention group
Group type: EXPERIMENTAL
Intervention: Visionaire PSI system (Smith and Nephew, Memphis, TN)
Number of subjects: 60
Study 29623574 — intervention group
Group type: COMPARATOR
Intervention: Conventional instrumentation
Number of subjects: 60
Study 26773446 — intervention group
Group type: EXPERIMENTAL
Intervention: IDegAsp+IAsp
Number of subjects: 0
Study 26773446 — intervention group
Group type: COMPARATOR
Intervention: IDet+IAsp
Number of subjects: 0
Study 26165865 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression of the 4th ventricle
Number of subjects: 81
Study 26165865 — intervention group
Group type: COMPARATOR
Intervention: Sham compression of the fourth ventricle
Number of subjects: 81
Study 26165865 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 81
Study 23805899 — intervention group
Group type: EXPERIMENTAL
Intervention: Trophic enteral feeding
Number of subjects: 174
Study 23805899 — intervention group
Group type: COMPARATOR
Intervention: Full enteral feeding
Number of subjects: 174
Study 21923988 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple courses of antenatal corticosteroids (ACS) every 14 days until 33+6 weeks or birth
Number of subjects: 1858
Study 21923988 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1858
Study 21923988 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple courses of antenatal corticosteroids (ACS)
Number of subjects: 1858
Study 18819870 — intervention group
Group type: EXPERIMENTAL
Intervention: Delay time of 8 seconds (Group C)
Number of subjects: 60
Study 18819870 — intervention group
Group type: EXPERIMENTAL
Intervention: Delay time of 10 seconds (Group D)
Number of subjects: 60
Study 18819870 — intervention group
Group type: COMPARATOR
Intervention: Delay time of 4 seconds (Group A)
Number of subjects: 60
Study 18819870 — intervention group
Group type: COMPARATOR
Intervention: Delay time of 6 seconds (Group B)
Number of subjects: 60
Study 16707412 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid etanercept (50 mg/mL)
Number of subjects: 36
Study 16707412 — intervention group
Group type: COMPARATOR
Intervention: Reconstituted lyophilized etanercept (25 mg/mL)
Number of subjects: 36
Study 16707412 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid etanercept
Number of subjects: 36
Study 12702524 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm A (cisplatin 25 mg/m(2) day 1, weekly for 9 weeks, irinotecan 90 mg/m(2) day 1, on weeks 1, 3, 5, 7 and 9, etoposide 60 mg/m(2) days 1‐3, on weeks 2, 4, 6, 8)
Number of subjects: 60
Study 12702524 — intervention group
Group type: COMPARATOR
Intervention: Arm B (cisplatin 60 mg/m(2) day 1, irinotecan 60 mg/m(2) days 1, 8, 15, etoposide 50 mg/m(2) days 1‐3, every 4 weeks for four cycles)
Number of subjects: 60
Study 11197053 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 micrograms CIFN three times a week for 24 weeks
Number of subjects: 0
Study 11197053 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 micrograms CIFN three times a week for 24 weeks
Number of subjects: 0
Study 8832006 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cells with purged or unpurged bone marrow (BM)
Number of subjects: 153
Study 8832006 — intervention group
Group type: COMPARATOR
Intervention: Autologous hematopoietic stem cells with unpurged peripheral blood stem cells (PBSCs)
Number of subjects: 153
Study 8832006 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cells with purged or unpurged BM
Number of subjects: 153
Study 8832006 — intervention group
Group type: COMPARATOR
Intervention: Autologous hematopoietic stem cells with unpurged PBSCs
Number of subjects: 153
Study 8832006 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients receiving BM
Number of subjects: 153
Study 8832006 — intervention group
Group type: COMPARATOR
Intervention: Patients receiving PBSC +/‐ BM
Number of subjects: 153
Study 8832006 — intervention group
Group type: COMPARATOR
Intervention: Patients receiving unpurged PBSC alone
Number of subjects: 153
Study 8832006 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients receiving purged BM
Number of subjects: 153
Study 8832006 — intervention group
Group type: COMPARATOR
Intervention: Patients receiving unpurged PBSCs
Number of subjects: 153
Study 1399073 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydron root canal fillings
Number of subjects: 74
Study 1399073 — intervention group
Group type: COMPARATOR
Intervention: gutta‐percha/AH‐26 root canal fillings
Number of subjects: 74
Study 4057034 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg intramuscularly as a pre-anesthetic
Number of subjects: 39
Study 4057034 — intervention group
Group type: COMPARATOR
Intervention: NaCl (control)
Number of subjects: 39
Study 31644585 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-hour Training Course on Emotional Intelligence (TCEI)
Number of subjects: 54
Study 31644585 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study 29985964 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal dexamethasone treatment
Number of subjects: 179
Study 29985964 — intervention group
Group type: COMPARATOR
Intervention: No dexamethasone exposure (control group)
Number of subjects: 179
Study 27129624 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 212
Study 27129624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study 24803825 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus thalidomide
Number of subjects: 86
Study 24803825 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (non-drug group)
Number of subjects: 86
Study 22044195 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate Seed Oil (PSO) 400 mg capsules twice daily for 4 weeks
Number of subjects: 51
Study 22044195 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules twice daily for 4 weeks
Number of subjects: 51
Study 20488410 — intervention group
Group type: EXPERIMENTAL
Intervention: Overlapping sirolimus-eluting stents (SES)
Number of subjects: 77
Study 20488410 — intervention group
Group type: EXPERIMENTAL
Intervention: Overlapping paclitaxel-eluting stents (PES)
Number of subjects: 77
Study 20488410 — intervention group
Group type: EXPERIMENTAL
Intervention: Overlapping zotarolimus-eluting stents (ZES)
Number of subjects: 77
Study 20488410 — intervention group
Group type: EXPERIMENTAL
Intervention: Overlapping bare-metal stents (BMS)
Number of subjects: 77
Study 20488410 — intervention group
Group type: COMPARATOR
Intervention: Nonoverlapping bare-metal stents (BMS)
Number of subjects: 77
Study 20488410 — intervention group
Group type: COMPARATOR
Intervention: Nonoverlapping drug-eluting stents (DES)
Number of subjects: 77
Study 20488410 — intervention group
Group type: EXPERIMENTAL
Intervention: Overlap segments of drug-eluting stents (DES)
Number of subjects: 77
Study 18630591 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) treatment with 'Xiusanzhen' technique.
Number of subjects: 60
Study 18630591 — intervention group
Group type: COMPARATOR
Intervention: Medication group (Duxil, 40 mg/time, 2 times/d for 10 weeks).
Number of subjects: 60
Study 15951469 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (anti-CD20 monoclonal antibody)
Number of subjects: 102
Study 15951469 — intervention group
Group type: EXPERIMENTAL
Intervention: Body surface area-based dosing
Number of subjects: 102
Study 15951469 — intervention group
Group type: EXPERIMENTAL
Intervention: Body surface area alone
Number of subjects: 102
Study 12898883 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoriatic patients
Number of subjects: 15
Study 12898883 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 15
Study 10715370 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of tamoxifen twice daily for 1 day followed by 800 micrograms of saline‐moistened misoprostol vaginally
Number of subjects: 150
Study 10715370 — intervention group
Group type: COMPARATOR
Intervention: Placebo twice daily for 1 day followed by 800 micrograms of saline‐moistened misoprostol vaginally
Number of subjects: 150
Study 10715370 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of tamoxifen
Number of subjects: 150
Study 10715370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 10715370 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of tamoxifen and misoprostol
Number of subjects: 150
Study 10715370 — intervention group
Group type: COMPARATOR
Intervention: Placebo and misoprostol
Number of subjects: 150
Study 7854523 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-positive subjects
Number of subjects: 207
Study 7854523 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-positive subjects with CD4 < or = 200
Number of subjects: 207
Study 1952856 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin, 500 mg every 12 h orally for 7 to 10 days
Number of subjects: 65
Study 1952856 — intervention group
Group type: COMPARATOR
Intervention: Parenteral aminoglycoside for 7 to 10 days
Number of subjects: 65
Study 1952856 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 65
Study 1952856 — intervention group
Group type: COMPARATOR
Intervention: Aminoglycosides
Number of subjects: 65
Study 1952856 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin and aminoglycoside
Number of subjects: 65
Study 7064026 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg
Number of subjects: 8
Study 7064026 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 0.6 mg after metoclopramide
Number of subjects: 8
Study 7064026 — intervention group
Group type: COMPARATOR
Intervention: Atropine 0.6 mg
Number of subjects: 8
Study 7064026 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg after atropine
Number of subjects: 8
Study 30295721 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative inspiratory muscle training (IMT) for 2 weeks
Number of subjects: 60
Study 30295721 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 29108407 — intervention group
Group type: EXPERIMENTAL
Intervention: Propacetamol (2 grams intravenously for 20 minutes before anesthesia)
Number of subjects: 98
Study 29108407 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 98
Study 26914296 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g of magnesium sulphate intravenously
Number of subjects: 30
Study 26914296 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 30
Study 25702375 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheelchair Self-Efficacy Enhanced for Use (WheelSeeU) training
Number of subjects: 40
Study 22269160 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (20 mg/day after up-titration over 4 weeks)
Number of subjects: 278
Study 22269160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278
Study 22269160 — intervention group
Group type: COMPARATOR
Intervention: Memantine and Placebo (comparison)
Number of subjects: 278
Study 22269160 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients not treated with acetyl cholinesterase inhibitors (AChEIs)
Number of subjects: 278
Study 22269160 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 278
Study 22269160 — intervention group
Group type: COMPARATOR
Intervention: Memantine and Placebo (correlation)
Number of subjects: 278
Study 20680188 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg/d for 4 weeks
Number of subjects: 24
Study 17244775 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 0
Study 17244775 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicted cumulative area under the curve model
Number of subjects: 0
Study 17244775 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical subgroup analysis
Number of subjects: 0